Late Development & Submission
Submission-Ready Benefit-Risk Analysis for Phase III and Regulatory Filing
CTD Module 2.5 benefit-risk sections, advisory committee preparation, and integrated safety-efficacy assessment — built from your data.
The regulatory submission is the moment when benefit-risk analysis becomes a formal deliverable. ArcaScience's platform supports Phase III and submission teams by integrating pivotal trial data with real-world evidence, producing quantified benefit-risk assessments aligned with FDA and EMA expectations, and generating the CTD Module 2.5 benefit-risk section directly from the analytical framework. For programs facing advisory committee review, the platform produces the structured analyses and visualizations that committee members expect.
The Challenge
The Evolving Standard for Benefit-Risk in Regulatory Submissions
Regulatory expectations for structured, quantitative benefit-risk assessment in submissions have increased substantially. FDA's Structured Benefit-Risk Framework, established through PDUFA V and VI commitments, sets explicit expectations for how benefit-risk should be presented. EMA's emphasis on quantified benefit-risk evaluation in MAA submissions continues to intensify. ICH M4E guidance on the Clinical Overview (Module 2.5) requires a coherent benefit-risk narrative that integrates across the entire clinical development program. Advisory committee briefing documents now routinely include structured benefit-risk presentations. Yet most submissions still rely on qualitative narratives rather than structured, quantified frameworks — creating a gap between what regulators expect and what sponsors deliver.
Qualitative Narratives Are Insufficient
Regulators at FDA and EMA increasingly expect quantified benefit-risk presentations with effects tables, value trees, and scenario analyses. Narrative-only submissions face more questions and longer review cycles.
12-18 Month Production Timelines
Comprehensive benefit-risk assessments for NDA/MAA submission take 12-18 months using traditional approaches — manual data aggregation, medical writing, iterative review cycles — compressing the window for competitive launch timing.
Advisory Committee Preparation Gap
Advisory committees expect quantitative benefit-risk presentations and scenario analyses. Preparing these requires integrating clinical data with external evidence under tight timelines, often with weeks between notification and the committee meeting.
How ArcaScience Addresses This
Integrating Pivotal Data with Contextual Evidence
Pivotal Trial & Real-World Data Integration
Integrate Phase III safety and efficacy endpoint data with real-world evidence on comparators, background adverse event rates, and class-level effects. The Data Intelligence Engine draws from AS Profiling Base 100b to contextualize pivotal trial findings within the broader evidence landscape, providing the comparative context regulators require.
Quantitative BRA & Advisory Prep
Generate comprehensive benefit-risk assessments using effects tables, value trees, and MCDA aligned with BRAT framework methodology. Produce subpopulation analyses (by demographic, comorbidity, and region), sensitivity analyses showing how conclusions change under different assumptions, and scenario modeling for advisory committee "what if" questions.
CTD Module 2.5 & Submission Documents
Generate the CTD Module 2.5 benefit-risk section directly from the quantitative framework, formatted per ICH M4E with cross-references to Module 2.7 clinical summary and Module 5 study reports. Produce advisory committee briefing materials with effects tables, forest plots, and structured scenario analyses. Internal consistency is guaranteed: the document reflects exactly what the analysis shows.
Workflow
How It Works
Integrate Pivotal Trial Data
Ingest Phase III clinical trial data — safety endpoints, efficacy outcomes, and subpopulation results — alongside comparator evidence from AS Profiling Base 100b.
Run Quantitative Benefit-Risk Assessment
Decision Intelligence applies BRAT framework, MCDA, and 24 proprietary AI models to produce structured effects tables, value trees, and quantitative evaluations with sensitivity analyses.
Prepare Advisory Committee Materials
Generate scenario analyses, forest plots, and structured presentations formatted for CHMP, PRAC, or FDA advisory committee briefing documents with anticipatory "what if" modeling.
Generate Submission-Ready CTD 2.5
Produce the CTD Module 2.5 benefit-risk section directly from the analytical framework, with ICH M4E formatting and cross-references to Modules 2.7 and 5.
Case Study — Sanofi
Thromboembolic Risk Detection That Re-Routed a Development Investment
Sanofi's team used ArcaScience's platform to conduct a benefit-risk assessment that identified a previously undetected thromboembolic risk signal. The finding informed the decision to re-route significant development investment before Phase III commitment — demonstrating how integrated, quantitative BRA can change the trajectory of a development program.
Read Full Case Study →VP Drug Safety
Sanofi — Thromboembolic Risk Program
Related Solutions
Benefit-Risk Analysis Across the Lifecycle
Early Development
Phase I-II signal detection, DDI screening, comparator profiling, and early benefit-risk framing.
Post-Marketing Surveillance
Automated PSUR/PBRER generation, continuous signal monitoring, RMP updates, label change support.
Market Access & HEOR
Value dossiers, HTA submission support, comparative effectiveness evidence, payer communication materials.